Sign in
Taking peopleNo phase

Marker miRNA 371 in newly diagnosed testicular germ cell tumor

Studies miRNA 371 in people newly diagnosed with testicular germ cell tumor.

Key facts

Who runs it
Fondazione del Piemonte per l'Oncologia
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors
Status
Recruiting
People taking part
100 people, planned
Started
1 Jul 2021
Expected to end
31 Dec 2026
Type of study
Observational, 2 groups
Record updated
5 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men aged 18 or older with a newly diagnosed germ cell tumor. It studies whether the blood marker miRNA 371 shows if active tumor is present.

Age
18 years or older
Sex
Male
Disease stage
New germ cell tumor, confirmed by tissue test or by raised HCG/AFP blood levels. Any site, stage or subtype can join, including a later second germ cell tumor. Only low or moderate risk of the disease coming back.
Earlier treatment
Men with Clinical Stage I testicular cancer who have surgery planned must have had the testicle removed (orchiectomy) within 42 days before registration.
Biomarker or test result
Blood tests for beta-HCG, AFP and LDH within 42 days before registration.

Main reasons for not taking part

  • High risk of the disease coming back
  • Cancer that has spread (metastatic disease)
  • Tumor checks done outside the time frame set by the protocol
  • Not able to follow the study schedule

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients must be ≥ 18 years of age
  • Patients must have a new diagnosis of a germ cell tumor confirmed pathologically or serologically (diagnostic elevation of HCG/AFP). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible
  • If surgery is planned, male patients with Clinical Stage I testicular cancer must have orchiectomy completed within 42 days prior to registration
  • Patients must have risk of relapse assessment determined by the local investigator prior to registration
  • Patients must have initial imaging, laboratory and other clinical evaluations (see below) performed within 42 days prior to registration. Imaging reports, pathology reports and performance status will be collected
  • Patients must have beta-human chorionic gonadotropin (beta-HCG), alpha- fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration
  • Patients must agree to provide informed consent and required blood specimens for the duration of the study

Who cannot take part

  • Patients with high risk of relapse or metastatic disease
  • Patients with tumour assessments beyond the time frame required by the protocol
  • Patients not complaint with the protocol schedule

This trial is currently available in Italy.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a observational study aimed at evaluating miRNA 371a-3p (miRNA 371) as a specific marker for presence or absence of clinically detectable viable germ cell malignancy.

The 2 groups in the trial

  • Low risk of relapse

    Low risk of relapse (5-25% chance of recurrence with active germ cell malignancy): patients with low risk designation will be assigned to a low intensity schedule of biospecimen collection and imaging requirements.

  • Moderate risk of relapse

    Moderate risk of relapse (26-50% chance of recurrence): patients with moderate risk designation will be assigned to a higher intensity schedule of biospecimen collection and imaging requirements including early repeat imaging and classic marker determination.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Observational Cohort Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumor
Plain-language title
Marker miRNA 371 in newly diagnosed testicular germ cell tumorGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
5 March 2026